SLNO Stock Summary and Trading Ideas (Soleno Therapeutics | NASDAQ:SLNO)

Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine.

Soleno Therapeutics trades on the NASDAQ stock market under the symbol SLNO.

As of April 24, 2024, SLNO stock price declined to $39.34 with 315,950 million shares trading.

SLNO has a beta of 0.33, meaning it tends to be less sensitive to market movements. SLNO has a correlation of 0.00 to the broad based SPY ETF.

SLNO has a market cap of $1.31 billion. This is considered a Small Cap stock.

In the last 3 years, SLNO stock traded as high as $53.82 and as low as $.85.

The top ETF exchange traded funds that SLNO belongs to (by Net Assets): XBI, VTI, DWAS, VXF, LABU.

SLNO has outperformed the market in the last year with a return of +895.9%, while the SPY ETF gained +24.2%. However, in the most recent history, SLNO shares have underperformed the stock market with its stock returning -18.2% in the last 3 month period and -4.3% for the last 2 week period, while SPY has returned +4.6% and -2.7%, respectively.

SLNO support price is $38.72 and resistance is $41.56 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that SLNO stock will trade within this expected range on the day.